Comments
Drug firm Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator for Azelastine Hydrochloride Ophthalmic Solution used for the treatment of allergic conjunctivitis.
The approved product is therapeutically equivalent to the reference listed drug Optivar Ophthalmic Solution of Mylan Specialty L P.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, Alembic Pharmaceuticals said in a BSE filing.
Quoting IQVIA data, Alembic Pharmaceuticals said Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, has an estimated market size of $8.5 million for 12 months ending December 2018.
The company currently has a total of 89 ANDA approvals (76 final approvals and 13 tentative approvals) from the USFDA, it added.
Shares of Alembic Pharmaceuticals were trading 0.55 per cent lower at Rs 537 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.